Nasdaq

Achieve Life Sciences to Present Phase 3 Study Findings on Cytisinicline for Smoking Cessation at 2025 ATS Conference

Achieve Life Sciences will present Phase 3 study data on cytisinicline's efficacy in nicotine craving reduction at the ATS Conference. Achieve Life Sciences, Inc. has announced that additional ...
Seeking Alpha

AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024

THOUSAND OAKS, Calif., April 16, 2024 /PRNewswire/ -- Amgen (AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE ® (tezepelumab-ekko) in chronic obstructive ...
Seeking Alpha

Press Release: Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine

Dupixent is the first and only investigational biologic for COPD that has demonstrated a significant reduction in moderate or severe acute exacerbations by 30% compared to placebo Dupixent is the ...
Nasdaq

Verona Pharma Presents Positive Phase 3 Analyses of Ohtuvayre® for COPD at ATS 2025

Verona Pharma plc has announced the upcoming presentation of ten posters at the American Thoracic Society Conference 2025, highlighting analyses from its Phase 3 ENHANCE studies of Ohtuvayre ...
WWLP-22News

Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine

NOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic ...